A parathyroid adenoma is a benign neoplasm of the parathyroid glands characterized by autonomous hypersecretion of parathyroid hormone (PTH) and loss of the normal control exerted by ionized calcium through the calcium-sensing receptor (CaSR). In clinical practice, it is the most common cause of primary hyperparathyroidism and, consequently, of PTH-dependent hypercalcemia, with integrated effects on bone, kidney and the cardiovascular system through alteration of the mineral regulation set-point. The condition does not necessarily present with a “classic” clinical picture. In many healthcare settings, a parathyroid adenoma is detected during investigations for mild hypercalcemia or for target-organ complications that are not immediately attributed to the parathyroid glands, such as recurrent nephrolithiasis or a progressive reduction in bone mineral density.
The importance of a parathyroid adenoma lies not only in the excess of PTH itself, but also in its ability to sustain high bone turnover, increase the filtered calcium load and thereby raise the risk of nephrolithiasis and nephrocalcinosis, and produce an inappropriate physiological state within the calcium-phosphate-vitamin D axis. Effective management therefore requires an approach that begins with biochemical diagnosis, continues with assessment of target-organ consequences and culminates in selection of the most appropriate treatment, which is often surgical. Treatment must be supported by monitoring capable of preventing post-treatment complications, particularly hypocalcemia and hungry bone syndrome.
Parathyroid adenoma accounts for most cases of primary hyperparathyroidism and explains how frequently this condition is encountered in internal medicine, nephrology, geriatrics and outpatient practice. Its epidemiology is closely related to how hypercalcemia is screened for and recognized. Where serum calcium measurement is routinely performed, primary hyperparathyroidism is often diagnosed at an early stage, with modest hypercalcemia and subtle symptoms. Where access to laboratory testing is more selective, symptomatic phenotypes characterized by nephrolithiasis, bone pain, skeletal fragility and neuromuscular abnormalities are more frequently observed. This apparent variability does not mean that the adenoma changes its biological nature, but rather that the timing of detection and the duration of exposure to elevated PTH differ.
The distribution by sex and age reflects the overall epidemiology of primary hyperparathyroidism, which tends to be more common in women and increases with age. In older adults, mild hypercalcemia may be incorrectly attributed to dehydration, medications or comorbidities, and a parathyroid adenoma may manifest predominantly through renal or skeletal complications. Conversely, in younger patients, identification of PTH-dependent hypercalcemia should promptly raise consideration of familial or syndromic forms, because the pre-test probability of a genetic predisposition increases when onset occurs at an early age or when multiple endocrine disorders coexist.
Among the principal risk factors and associated clinical settings, previous neck irradiation or therapeutic radiation exposure represents an important consideration and has historically been linked to a higher incidence of cervical endocrine disease. Although the causal relationship is complex, a history of radiation exposure requires more cautious and comprehensive interpretation of PTH-dependent hypercalcemia. Another relevant setting is chronic disturbance of mineral and vitamin D metabolism. Vitamin D deficiency may mask the severity of primary hyperparathyroidism by limiting hypercalcemia while accentuating PTH elevation, thereby making skeletal damage more prominent. Conversely, correction of the deficiency may reveal more marked hypercalcemia in a patient with an adenoma because the limitation on intestinal calcium absorption is removed.
Clinical vulnerability is also determined by factors that are not etiological but have prognostic relevance. Reduced renal function, a history of nephrolithiasis, predisposition to osteoporosis, menopause, immobility and frailty increase the likelihood that an adenoma will present through complications. The clinical epidemiology of parathyroid adenoma is therefore intertwined with that of chronic conditions affecting adults and older people, as well as with the use of medications that influence calcium and PTH, including thiazide diuretics and lithium. These agents may alter interpretation of laboratory findings or worsen hypercalcemia in a predisposed individual.
Finally, a minority of cases involving adenomas or related parathyroid lesions occur within inherited syndromes. In these settings, the risk is not simply that of developing an adenoma, but of presenting with multigland disease or a different natural history, with direct implications for surgical strategy, follow-up and family counseling. Although less common, this epidemiological aspect is crucial because it represents one of the main circumstances in which an initial diagnostic error may have lasting effects on clinical outcome.
A parathyroid adenoma arises from clonal proliferation of parathyroid cells that acquire the ability to secrete PTH in an inappropriate manner relative to the concentration of ionized calcium. Under physiological conditions, the CaSR located on the membrane of parathyroid chief cells is the key sensor regulating PTH secretion. When serum calcium rises, CaSR signaling rapidly suppresses hormone release. When serum calcium falls, secretion increases to restore equilibrium. In an adenoma, this feedback circuit becomes less effective because the set-point is shifted and the gland interprets higher calcium concentrations as acceptable, continuing to produce PTH despite hypercalcemia.
From a pathogenetic perspective, recurrent molecular pathways that promote cell growth and functional autonomy have been identified. Alterations involving cell-cycle regulators such as cyclin D1, together with loss of function of tumor suppressor genes associated with inherited predisposition, including MEN1 and CDC73, illustrate how proliferative biology and calcium-sensing biology may converge to produce the final hypersecretory phenotype. In most sporadic cases, detailed molecular characterization is not required to establish the diagnosis or guide treatment. However, understanding these mechanisms helps explain why certain presentations are more aggressive, why multiple glands may occasionally be involved and why some lesions belong to a spectrum that includes rarer and biologically distinct entities.
The pathophysiology of parathyroid adenoma is dominated by the actions of PTH on the kidneys and skeleton and by its interaction with active vitamin D. In the kidneys, PTH increases tubular calcium reabsorption, reduces phosphate reabsorption and promotes phosphaturia, while stimulating the enzyme 1-alpha-hydroxylase and increasing production of calcitriol. This produces a characteristic combination of hypercalcemia, low or inappropriately normal phosphate and a relative increase in active vitamin D availability, which enhances intestinal calcium absorption. Clinical reality is more complex because 25(OH)D deficiency is common and may attenuate the rise in calcitriol and modify the biochemical profile, resulting in phenotypes characterized by elevated PTH, mild hypercalcemia and substantial skeletal damage.
Within the skeleton, chronic PTH excess produces high bone turnover and accelerated remodeling, with an imbalance favoring resorption, particularly in cortical bone. The result is reduced bone strength, which may manifest as osteopenia, osteoporosis and fragility fractures. In more severe and prolonged cases, osteitis fibrosa may develop, with bone pain, deformities and radiological abnormalities. The most clinically relevant consideration is that skeletal damage is often silent until sentinel events such as fractures or loss of vertebral height occur. Pathophysiological understanding must therefore be translated into active target-organ assessment even when the patient reports no obvious skeletal symptoms.
The kidney is the other major target organ. Although PTH promotes renal calcium reabsorption, hypercalcemia increases the filtered calcium load and may lead to hypercalciuria, creating an environment favorable to nephrolithiasis and nephrocalcinosis. Hypercalcemia may also impair urinary concentrating ability and promote polyuria and dehydration, which in turn increase the risk of stone formation. Over time, the combination of mineral deposits, episodic obstruction, infections and hemodynamic alterations may contribute to declining renal function, particularly in older patients or in those with renovascular comorbidities.
Systemic effects also occur and explain symptoms that are frequently underestimated, including fatigue, reduced cognitive performance, mood disturbances, diffuse pain, proximal weakness and gastrointestinal abnormalities. These manifestations are nonspecific and are therefore often attributed to other conditions. Nevertheless, their persistence in the presence of PTH-dependent hypercalcemia is consistent with the pathophysiology of parathyroid adenoma and should be incorporated into clinical reasoning because they affect quality of life and the expected benefit of treatment.
The clinical presentation of parathyroid adenoma depends on the duration of exposure to elevated PTH, the severity of hypercalcemia and the functional reserve of bone and kidney. Many patients are identified at an early stage, with mild hypercalcemia and subtle symptoms, whereas others first present with established complications. Careful reconstruction of the medical history is therefore essential, and common symptoms should be interpreted from an endocrine and metabolic perspective when the biochemical context supports this possibility.
A frequent group of historical manifestations involves the neuromuscular and neuropsychiatric systems, including fatigue, reduced exercise tolerance, proximal weakness, drowsiness or sleep disturbances, impaired concentration and irritability. In some patients, particularly older adults, the clinical picture may be dominated by an overall decline in performance and worsening frailty and deconditioning rather than by pain or classic symptoms. Gastrointestinal manifestations may include reduced appetite, nausea, constipation and dyspepsia. Although nonspecific, these symptoms become clinically meaningful when they are associated with hypercalcemia and signs of dehydration.
Renal history is often a discriminating element. Episodes of renal colic, recurrent stones, complicated urinary tract infections, passage of urinary gravel or ultrasound evidence of microlithiasis should be regarded as potential signs of primary hyperparathyroidism caused by an adenoma. At the same time, polyuria and polydipsia may reflect the renal effects of hypercalcemia and contribute to a vicious cycle of dehydration, increasing serum calcium and worsening systemic symptoms.
From a skeletal perspective, patients may report diffuse bone pain, chronic low back pain, loss of height or fragility fractures, particularly involving the vertebrae, wrist or proximal humerus. However, the absence of pain does not exclude skeletal damage. Reduced bone mineral density and subclinical vertebral fractures may be present without symptoms and become apparent only through targeted assessment. Muscle weakness and postural instability also increase the risk of falls, transforming skeletal impairment into a concrete clinical hazard.
Findings on physical examination may be nonspecific. Signs of dehydration, reduced proximal muscle tone, elicitable bone tenderness and an unstable gait may be present in more advanced disease. With more marked hypercalcemia, changes in mental status, including confusion or psychomotor slowing, may occur, particularly in older patients or in association with infection, diuretic use, reduced fluid intake or renal impairment. In this context, a parathyroid adenoma acts as a risk multiplier for acute events because relatively small changes in hydration status or medication use may rapidly disrupt metabolic balance.
Some patients experience symptoms at the boundary between nonspecific and attributable, including headache, paresthesia, migrating pain or impaired sleep quality. In such cases, the clinical value lies in recognizing overall coherence. The combination of hypercalcemia, non-suppressed PTH and evidence of renal or skeletal involvement is compatible with a parathyroid adenoma and justifies comprehensive investigation even when no single pathognomonic symptom is present.
Suspicion of a parathyroid adenoma most commonly arises from identification of hypercalcemia associated with an inappropriately normal or elevated PTH concentration. This concept is fundamental. In the presence of hypercalcemia, a normal PTH value is not physiological because PTH should be suppressed. Failure of suppression suggests a PTH-dependent mechanism and makes an adenoma likely within the context of primary hyperparathyroidism. Consequently, every case of hypercalcemia confirmed on repeated testing requires an assessment that includes PTH and evaluation of mineral metabolism, avoiding reductive interpretations based on a single result or transient condition.
Clinical suspicion should be particularly high in the presence of recurrent nephrolithiasis, nephrocalcinosis, otherwise unexplained reduction in renal function or significant hypercalciuria, especially when constipation, fatigue and polyuria coexist. A diagnosis of osteoporosis with a pattern not explained by age, fragility fractures or subclinical vertebral fractures should also prompt consideration of primary hyperparathyroidism because excessive PTH may be the principal biological driver of bone loss. In these settings, suspicion is not merely theoretical. It changes the diagnostic pathway and treatment strategy, with the potential to substantially reduce recurrent stone formation and improve skeletal stability.
A typical clinical setting is the occurrence of nonspecific neurocognitive and neuromuscular symptoms, such as chronic fatigue, reduced concentration and proximal weakness, in association with mild or moderate hypercalcemia. Because these symptoms are common to many disorders, the threshold for suspecting an adenoma should depend on the presence of a biochemical signal and its consistency with target-organ involvement. In older patients, hypercalcemia may manifest as worsening delirium, falls or functional decline. In this context, identifying the adenoma is a decisive step in preventing recurrent episodes and reducing the risk of hypercalcemic crises under precipitating conditions.
Suspicion should also be broadened when onset occurs at an early age, when hyperparathyroidism recurs or when there is a family history of endocrine disorders, neuroendocrine tumors, pituitary disease or pancreatic disease. In these cases, the possibility of an inherited syndrome requires consideration of multigland disease or a biological pattern different from that of a sporadic adenoma, with implications for surgical planning, imaging strategy and long-term follow-up. Exposure to medications such as lithium or diuretics that affect serum calcium and PTH also requires caution. Such exposure does not exclude an adenoma, but it may alter its presentation and must be incorporated into the decision-making process.
In summary, a parathyroid adenoma should be suspected whenever the PTH-calcium axis behaves in a non-physiological manner, particularly when renal or skeletal damage is present. Suspicion should be translated rapidly into targeted investigations because etiological characterization and identification of target-organ involvement determine the urgency and direction of treatment.
The diagnosis of a parathyroid adenoma does not coincide with radiological localization of the lesion. It depends on demonstration of primary hyperparathyroidism and assessment of its clinical consequences. The first step is reliable confirmation of hypercalcemia, preferably through repeated measurement of total calcium corrected for albumin and, when indicated, ionized calcium, because changes in albumin, dehydration and pre-analytical errors may affect interpretation. Once hypercalcemia has been confirmed, measurement of intact PTH is the key discriminatory test. An elevated or non-suppressed PTH value in the presence of hypercalcemia suggests a PTH-dependent mechanism and indicates the need for comprehensive assessment of mineral metabolism.
The initial panel should include phosphate, creatinine with estimation of the glomerular filtration rate, 25(OH)D and concurrent evaluation of urinary calcium excretion. Vitamin D assessment is crucial because deficiency may raise PTH and mask the severity of hypercalcemia, while correction of the deficiency may alter serum calcium and clarify the primary nature of the disorder. Renal assessment is required not only to estimate risk and determine the indication for surgery, but also to interpret urinary findings correctly and distinguish primary hyperparathyroidism from secondary or mixed conditions.
Diagnostic assessment of parathyroid adenoma
An important diagnostic step is differentiation from familial hypocalciuric hypercalcemia, because this condition may present with mild hypercalcemia and non-suppressed PTH and may therefore be confused with primary hyperparathyroidism. Twenty-four-hour urinary assessment and calcium excretion indices can be helpful but are not infallible. Diagnostic gray zones occur, particularly in the presence of renal impairment, vitamin D deficiency or diuretic use. In uncertain cases, family history, long-term stability of hypercalcemia, the presence or absence of target-organ complications and, when indicated, genetic testing become part of the diagnostic process because an error may lead to unnecessary surgery.
Once primary hyperparathyroidism compatible with a parathyroid adenoma has been diagnosed, the next stage is assessment of severity and complications. From a skeletal perspective, bone densitometry using dual-energy X-ray absorptiometry (DXA) should include standard sites and, when indicated, vertebral assessment to identify subclinical fractures. From a renal perspective, it is important to assess any history of renal colic, perform urinalysis, evaluate renal function and use imaging to detect stones or nephrocalcinosis, because these complications alter the indication for and urgency of treatment. In symptomatic patients or those with more marked hypercalcemia, the electrolyte profile and fluid balance should be monitored because dehydration may rapidly worsen serum calcium and amplify symptoms.
Localization imaging must be interpreted correctly. Its purpose is to plan surgery, not to establish the diagnosis. First-line techniques include neck ultrasound and sestamibi scintigraphy, preferably combined with single-photon emission computed tomography/computed tomography (SPECT/CT) when available because this improves anatomical localization. When findings are negative or discordant, or when an ectopic location is suspected, further assessment using four-dimensional computed tomography (4D-CT) or positron emission tomography techniques such as fluorocholine PET may be appropriate in experienced centers, particularly in patients undergoing reoperation or in disease that is difficult to localize. Inappropriate procedures such as preoperative biopsy of the lesion should be avoided because they are unnecessary and may increase risk without providing a genuine diagnostic advantage in the appropriate clinical context.
The final diagnostic stage is integration of biochemical confirmation, exclusion of the principal alternatives, quantification of target-organ damage and functional localization for surgery. Only this integrated assessment allows accurate determination of whether the patient has a single sporadic adenoma, probable multigland disease or a syndromic condition, and therefore permits selection of the safest and most effective treatment strategy.
Classification of parathyroid adenoma has clinical value because it links disease biology with treatment indications, the type of surgery and follow-up. The first distinction concerns the context of primary hyperparathyroidism. In most patients, an adenoma represents single-gland disease, whereas a minority have multigland disease or conditions in which several glands are hyperfunctioning. This distinction is not merely technical. It affects the likelihood of success of a focused surgical approach and the need for broader exploration when localization is uncertain or when the clinical profile suggests involvement of multiple glands.
A second classification is based on the clinical phenotype. Symptomatic forms may present with nephrolithiasis, fractures, bone pain, marked weakness or clinically significant hypercalcemia, whereas other forms are detected incidentally with mild hypercalcemia and nonspecific symptoms. This distinction must be interpreted cautiously because the absence of symptoms does not imply the absence of damage. Many apparently paucisymptomatic patients already have reduced bone mineral density, vertebral microfractures or a history of unrecognized microlithiasis. Severity should therefore be defined primarily according to target-organ involvement and the extent of biochemical disturbance rather than solely on the patient’s subjective perception of symptoms.
Biochemical severity may be described according to the concentration of serum calcium, the level of PTH, the presence of hypercalciuria and the degree of renal impairment. More marked hypercalcemia increases the risk of dehydration and neurological symptoms and makes urgent management more likely, whereas very high PTH and markedly increased bone turnover raise the risk of significant postoperative hypocalcemia due to hungry bone syndrome. In practical terms, these features are not merely labels but tools for anticipating risks and planning treatment and perioperative monitoring.
Another useful classification distinguishes sporadic from inherited disease. When primary hyperparathyroidism occurs at a young age, recurs, is associated with other endocrine tumors or arises in the setting of a suggestive family history, the adenoma may be part of a genetic syndrome or a predisposition to multigland disease. In such cases, the aim is not only to correct hypercalcemia but also to establish a strategy that reduces the risks of persistent disease, recurrence and long-term complications, including counseling and surveillance for other possible endocrine manifestations.
Finally, classification should include awareness that rare parathyroid lesions may mimic an adenoma clinically or radiologically while exhibiting different behavior. The distinction between a typical adenoma, lesions with atypical features and carcinoma is predominantly histological and postoperative. Nevertheless, clinical and biochemical warning signs such as very severe hypercalcemia, a palpable mass or marked target-organ damage should increase diagnostic vigilance and prompt specialist management, while recognizing that most cases remain benign.
Treatment of parathyroid adenoma aims to eliminate the source of PTH hypersecretion, correct hypercalcemia and prevent or halt progression of bone and kidney damage. The standard treatment is parathyroidectomy, the only potentially curative approach. When performed in experienced centers, it offers a high probability of sustained normalization of serum calcium. The decision to operate depends on symptoms, target-organ complications and the patient’s risk profile. Surgery may also be indicated in apparently asymptomatic disease when criteria related to serum calcium, bone, kidney or age are present, because the objective is not simply to lower serum calcium but to prevent fractures, kidney stones and progressive renal impairment.
Preparation for treatment should begin with stabilization of mineral physiology. In patients with moderate or significant hypercalcemia, adequate hydration and review of medications that increase serum calcium are essential for reducing perioperative risk and improving clinical safety. Correction of vitamin D deficiency requires a cautious and monitored strategy. Restoring 25(OH)D is useful for reducing relative hyperparathyroidism and improving skeletal status, but serum calcium must be monitored to avoid an unexpected worsening of hypercalcemia. In patients with marked skeletal fragility or very high bone turnover, planning should include prevention of postoperative hypocalcemia because the abrupt fall in PTH may trigger rapid movement of calcium into the skeleton.
Surgery may be performed using a focused approach when imaging consistently localizes a single lesion and the clinical context suggests single-gland disease. In these cases, intraoperative PTH monitoring allows real-time assessment of the adequacy of excision. A rapid fall in PTH after removal of the hyperfunctioning gland supports the likelihood of cure and reduces the need for extensive exploration. When imaging is negative or discordant, multigland disease is suspected or the patient has a syndromic profile, a broader exploration and more complex surgical strategy may be required to reduce the risk of persistent or recurrent disease.
Not all patients can or wish to undergo surgery. In these cases, medical management may be used to control serum calcium and protect the skeleton. Calcimimetics such as cinacalcet lower serum calcium by increasing CaSR sensitivity and are particularly useful when the primary objective is to control hypercalcemia, although they do not remove the underlying cause. For skeletal protection, antiresorptive agents such as bisphosphonates or denosumab may be used to improve bone mineral density and reduce fracture risk, particularly when surgery is postponed or contraindicated. This strategy must be accompanied by regular monitoring because pharmacological control does not eliminate the risk of stone formation and does not replace assessment of disease progression.
The choice between surgery and medical management must be individualized and based on a balance between expected benefits and risks. In a young patient with skeletal or renal damage and a long life expectancy, the cumulative benefit of surgery is often substantial. In a frail patient with major comorbidities, the objective may be clinical stability with the lowest possible procedural risk. In both settings, treatment quality depends on a clearly structured pathway involving definition of target-organ involvement, serum calcium control, prevention of complications and continuity of long-term monitoring.
Follow-up of parathyroid adenoma depends on the selected treatment. After parathyroidectomy, immediate monitoring is directed toward prevention and management of hypocalcemia, which may occur because of reduced PTH and rapid calcium uptake by recovering bone. Serial monitoring of calcium, phosphate and, when appropriate, magnesium during the first 24 to 72 hours allows early detection of symptomatic hypocalcemia. In patients with advanced bone disease or very high preoperative PTH, the risk of hungry bone syndrome requires a planned approach to calcium and active vitamin D supplementation, with closer monitoring and management that may continue for weeks or months.
During intermediate-term postoperative follow-up, the objective is to document biochemical cure and clinical stability. Normalization of serum calcium is the principal marker, but interpretation of PTH must consider that transient adaptive phases may occur and that vitamin D deficiency or impaired renal function may maintain a relatively elevated PTH despite normal serum calcium. Follow-up must therefore include an integrated assessment and correction of factors that may confound the biochemical profile, avoiding premature diagnosis of persistent disease when the overall pattern is compatible with physiological recovery and readjustment.
Surveillance of target organs is an essential part of follow-up. From a skeletal perspective, bone mineral density tends to improve after removal of the source of excessive PTH, but the speed and extent of recovery depend on disease duration and age. Bone densitometry performed after an appropriate interval allows the recovery trajectory to be documented and any anti-osteoporotic treatment to be optimized. From a renal perspective, a history of stone disease should be reassessed and imaging used when indicated to verify the absence of recurrence or persistence of deposits. Normalization of serum calcium reduces risk but does not immediately eliminate the possibility of further events in individuals with a lithogenic predisposition.
In patients managed without surgery, follow-up must be structured and continuous. Regular biochemical surveillance of serum calcium and renal function allows progression to be identified, while skeletal and renal assessment may detect target-organ damage that changes an observable condition into one requiring definitive treatment. In patients receiving calcimimetics or antiresorptive agents, monitoring should include efficacy in controlling serum calcium, tolerability and periodic reassessment of overall risk because clinical needs may change with age, the development of new comorbidities or disease progression.
Quality of life is an often underestimated objective of follow-up. Symptoms such as fatigue, cognitive difficulties and diffuse pain may improve after treatment, but the response is variable and may require time. Careful assessment of residual symptoms helps distinguish slow recovery from metabolic complications, vitamin deficiencies and independent comorbidities, thereby improving the appropriateness of interventions and reducing the risk of attributing every complaint incorrectly to calcium metabolism.
The prognosis of parathyroid adenoma is generally favorable when the diagnosis is correct and treatment is appropriate for the patient’s profile. Surgery, in particular, provides a high probability of sustained normalization of serum calcium and reduction in the risk of renal and skeletal complications, with progressive improvement in bone turnover and, in many cases, bone mineral density. The recovery trajectory is influenced by the duration of exposure to elevated PTH. The longer bone and kidney have been subjected to metabolic stress, the greater the likelihood that some consequences will be only partially reversible or require a prolonged period to improve.
The principal complications of parathyroid adenoma result from untreated or late-treated disease. From a renal perspective, nephrolithiasis, nephrocalcinosis and decline in renal function are clinically significant outcomes. Prevention of recurrent stone formation is one of the most tangible benefits of definitive control of primary hyperparathyroidism. From a skeletal perspective, the risk of osteoporosis and fragility fractures, including subclinical vertebral fractures, is central because it affects independence and mortality in older adults and substantially reduces quality of life. Muscle weakness associated with the metabolic disorder also increases the risk of falls, establishing a direct relationship between endocrine disturbance and traumatic events.
Systemic complications related to hypercalcemia and excessive PTH may also occur, including neurocognitive disturbances, mood changes, constipation, dehydration and, in severe cases, altered mental status. Under predisposing conditions, hypercalcemia may contribute to acute episodes requiring urgent treatment. Overall prognosis therefore depends not only on the ability to normalize calcium and PTH, but also on the speed with which accumulation of target-organ damage is prevented and on the quality of monitoring used to avoid recurrence and complications.
Treatment-related complications are predominantly associated with surgery and postoperative metabolic rebalancing. Transient hypocalcemia is common, and when it is severe and prolonged because of skeletal calcium uptake it constitutes hungry bone syndrome, which requires intensive supplementation and monitoring. Outcome depends on preoperative preparation, the severity of skeletal disease and postoperative management. A structured pathway shortens the duration of symptoms and prevents cardiac and neuromuscular complications related to hypocalcemia. Other surgical complications, including dysphonia caused by recurrent laryngeal nerve involvement or local problems, depend on the experience of the center and the complexity of the case and must be balanced against the risk of leaving the patient exposed to chronic hypercalcemia and progressive target-organ damage.
Overall, parathyroid adenoma is histologically benign but may impose a substantial clinical burden if it is not recognized. The best prognosis is achieved when biochemical diagnosis is timely, imaging is used correctly to plan treatment and follow-up is directed toward protecting bone and kidney while ensuring continuity of long-term monitoring.